Position paper on the use of drug eluting stents (DES) in percutaneous coronary interventions in patients with coronary heart disease;Positionspapier zum einsatz von beschichteten stents (DES) bei perkutanen koronarinterventionen bei patienten mit koronarer herzerkrankung

Zeitschrift fur Kardiologie

Volumn 92, Issue 7, 2003, Pages 606-612

  Levenson, Benny ^a   Dietz, R ^b   Gottwik, M ^b   Meinertz, T ^b   Osterspey, A ^b   Strasser, R ^b   Tebbe, U ^b   Werdan, K ^b   Arnold, G ^b   Behrenbeck, D ^b   Fleck, E ^b   Trappe, H J ^b  

^a Kardiologische Gemeinschaftspraxis   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

BRACHYTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG FORMULATION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; REVIEW; SIDE EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY STENOSIS; COST-BENEFIT ANALYSIS; HUMANS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS;

EID: 10744232541     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-003-0970-z     Document Type: Review

References (74)

1. Ako J, Morino Y, Sonoda S et al (2003) Effects of sirolimus-eluting stents in diabetic patients volumetric intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 41:73A
2. Al Suwaidi J, Garratt KN, Berger PB et al (2000) Immediate and one-year outcome of intracoronary stem implantation in small coronary arteries with 2.5-mm stents. Am Heart J 140:898-905
3. Bennett MR, O'Sullivan M (2001) Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther 91:149-166
4. Briguori C, Sarais C, Pagnotta P et al (2002) In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol 40:403-409
5. CABRI trial participants (1995) First year results of CABRI (Coronary Angioplasty vs Bypass Revascularization Investigation). Lancet 346:1179-1184
6. Canos DA, Mintz GS, Shah VM et al (2003) Late in-stent restenosis occurring after 12 months is common and the predictors are similar to early in-stent restenosis. J Am Coll Cardiol 41:19A-20A
7. Casscells W (1992) Migration of smooth muscle cells and endothelial cells: critical events in restenosls. Circulation 86:723-729
8. Cohen DJ, Bakhai A, Shi C et al (2003) Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: results from the randomized SIRIUS trial. J Am Coll Cardiol 41:32A
9. Colombo A for the TAXUS II study group (2003) 12-month clinical follow-up of the TAXUS II paclitaxel-eluting stent study. Late breaking clinical trials in interventional cardiology II. Am Coll Cardiol 52nd Ann Sci Sess; 03/03, Chicago
10. Colombo A, Louvard Y, Raghu C et al (2003) Sirolimus-eluting stents in bifurcation lesions: six-months angiographic results according to the implantation technique. J Am Coll Cardiol 41:53A
11. Costa MA, Moses JW, Leon MB et al (2003) Sirolimus-eluting stent for the treatment of bypass graft disease: the initial US experience. J Am Coll Cardiol 41:13A
12. Degertekin M, Serruys PW, Foley DP et al (2002) Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stem implantation (First in Man clinical trial). Circulation 106:1610-1613
13. Detre KM, Holmes DR, Holubkow R et al (1990) Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 82:739-750
14. Ellis SG, Roubin GS, King SB III et al (1988) Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 77:372-379
15. Federal Register, part II, Department of Health and Human Services 42 CFR part 405 et al Medicare program (2002) Changes to the hospital inpatient prospective payment systems and fiscal year 2003 rates; final rule 67:50003-50005
16. Ferns GA, Raines EW, Sprugel KH et al (1991) Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253:1129-1132
17. Fischman DL, Leon MB, Baim DS et al for the Stent Restenosis Study Group (STRESS) (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331:496-501
18. Gerckens U, Buellesfeld L, Horstkotte D et al (2003) Evaluation of a tacrolimus-eluting coronary stent with nanoporous ceramic coating in treatment of native coronary artery lesions: phase I and II of the PRESENT study. J Am Coll Cardiol 41:7A
19. Gershlick AH, De Scheerder I, Chevalier B (2001) Local drug delivery to inhibit coronary artery restenosis. Data from the ELUTES (EvaLUation of pacliTaxel Eluting Stent) clinical trial. Circulation 104:II-416
20. Girt AK, Seabra-Gomes R, Bassand JP et al for SHAKESPEARE Registry (2003) Verwendung der Drug-eluting Stents seit Zulassung in Europa: Ergebnisse des Internationalen SHAKESPEARE Registers. ZfK 92(Suppl 1):I/1
21. Grube E, Buellesfeld L, Mueller R et al (2003) First human experience using a new everolimus stent coating: procedural and six-months follow-up results of the FUTURE trial. J Am Coll Cardiol 41:6A
22. Grube E, Lansky AJ, Reifart N et al (2002) SCORE 6 months angiographic results: improved restenosis in patients receiving the QUADDS-QP2 drug-eluting stent compared with the control bare stents. J Am Coll Cardiol 39:59A
23. Grube E, Silber S, Hauptmann KE et al (2003) TAXUS I: six- and twelve-months results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38-42
24. Grüntzig A (1978) Transluminal dilatation of coronary artery stenoses. Lancet 1:263
25. Hamm CW, Reimers J, Ischinger T et al (1994) A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease (GABI). N Engl J Med 331:1037-1043
26. Hamm CW, Senges J für das Cypher-Stent-Register (2003) Erste Ergebnisse des deutschen Drug-eluting Stent Registers. ZfK 92(Suppl 1):I/1
27. Henderson RA, Pocock SJ, Sharp SJ et al (1998) Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary artery bypass grafting. Lancet 352:1419-1425
28. Holmes DR, Leon MB, Moses JW et al (2003) One-year follow-up of the SIRIUS study: a randomized study with the sirolimus-eluting Bx Velocity stent in the treatment of patients with de-novo native coronary artery lesions. J Am Coll Cardiol 41:32A
29. Ip J, Fuster V, Israel D et al (1991) The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol 17:77B-88B
30. Kiemeneij F, Serruys PW, Macaya C et al (2001) Continued benefit of coronary stenting versus balloon angioplasty: 5-year clinical follow-up of BENESTENT-I trial J Am Coll Cardiol 37:1598-1600
31. Köster R, Hamm CW, Seabra-Gomes R et al (1999) Laser angioplasty of restenosed coronary stents. Results of a multicenter surveillance trial (LARS). J Am Coll Cardiol 34:25-32
32. Kuntz RE (1999) Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the Diabetes-Percutaneous Transluminal Coronary Angioplasty Dilemma. Circulation 99:847-851
33. Lafont A, Libby P (1998) The smooth muscle cell: sinner or saint in restenosis and the acute coronary syndromes? J Am Coll Cardiol 32:283-285
34. Leon MB, Holmes DR, Simonton C et al (2003) The impact of sirolimus-eluting stents in diabetics: results from the SIRIUS trial. J Am Coll Cardiol 41:54A
35. Macaya C, Serruys PW, Ruygrok P et al (1996) Continued benefit of coronary stenting versus balloon angioplasty: 1 year clinical follow-up of BENESTENT Trial. J Am Coll Cardiol 27:255-261
36. Marx SO, Jayaraman T, Go LO, Marks AR (1995) Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76:412-417
37. Matter CM, Kurz DJ, Wendt S (2002) Tacrolimus (FK506), but not Sirolimus (Rapamycin) targets human vasular smooth muscle cells (VSMC), but spares endothelial cells (EC)-implications for drug-eluting stents. Circulation 106:II-356-357
38. Mehran R, Mintz GS, Popma JJ et al (1996) Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol 78:618-622
39. Meier B (1988) Restenosis after coronary angioplasty: review of the literature. Eur Heart J (Suppl C):9:1-6
40. Morice MC, Serruys PW, Sousa JE et al (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. The RAVEL trial. N Engl J Med 346:1773-1780
41. Morice MC, Serruys PW, Constantini C et al (2003) Two-year follow-up of the RAVEL study: a randomized study with the sirolimus-eluting Bx Velocity stent in the treatment of patients with de-novo native coronary artery lesions. J Am Coll Cardiol 41:32A
42. Moses JW, Kereiakes D, Williams DO et al (2003) Should sirolimus-eluting stents be the new standard for left anterior descending therapy? A SIRIUS substudy. J Am Coll Cardiol 41:73A
43. Moussa I, Di Mario C, Di Francesco L et al (1996) Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Am J Cardiol 78:13-17
44. O'Neill WW, Midei MG, Cox DA (2003) The DELIVER trial: a randomized comparison of paclitaxel-coated versus metallic stents for treatment of coronary lesions. Late breaking clinical trials in interventional cardiology II. Am Coll Cardiol 52nd Ann Sci Sess; 03/03, Chicago
45. Park SJ, Shim WH, Ho DS et al (2003) A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348:1537-1545
46. Reeder GS, Krishan I, Nobrega FT et al (1984) Is percutaneous transluminal coronary angioplasty less expensive than bypass surgery? N Engl J Med 311:1157-1162
47. Regar E, Serruys PW, Bode C et al (2002) Angiographic findings of the multicenter randomized study with sirolimus-eluting Bx Velocity balloon-expandable stent (RAVEL). Circulation 106:1949-1956
48. Reifart N, Vandormael M, Krajcar M et al (1997) Randomized comparison of angioplasty of complex coronary lesions at a single-center. Excimer laser, rotational atherectomy, and balloon angioplasty comparison (ERBAC) study. Circulation 96:91-98
49. Reilly JP, Grise MA, Mehran R et al (2001) SCRIPPS II: a pilot trial of localized radiation therapy (brachytherapy) to inhibit restenosis after stenting. Circulation 104:II-546
50. RITA Trial Participants (1993) Coronary angioplasty vs coronary artery bypass surgery: the randomized intervention treatment of angina (RITA) trial. Lancet 341:573-580
51. Rodriguez A, Bernardi V, Navia J et al (2001) Argentine randomized study: coronary angioplasty with stenting vs coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30 days and one-year follow-up results. J Am Coll Cardiol 37:51-58
52. Ross R, Masuda J, Raines EW (1990) Cellular interactions, growth factors, and smooth muscle proliferation in atherogenesis. Ann NY Acad Sci 598:102-112
53. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126
54. Roubin GS, King III SB, Douglas JS Jr (1987) Restenosis after percutaneous transluminal coronary angioplasty: the Emory Ûniversity Hospital experience. Am J Cardiol 60:39B-43B
55. Saia F, Lemos PA, Degertekin M et al (2003) Sirolimus-eluting stents for treatment of in-stent restenosis in the real world: preliminary results from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 41:53A
56. Savage MP, Douglas JS, Fischman DL et al (1997) for the saphenous vein de novo trial (SAVED) Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med 337:740-747
57. Schampaert E, Reeves F, Traboulsi MD et al for C-SIRIUS The Canadian multicenter, randomized, double-blind study of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions: C-SIRIUS (2003). Late breaking clinical trials III. Am Coll Cardiol 52nd Ann Sci Sess; 04/03, Chicago
58. Schofer, Schlüter M et al for the E-SIRIUS investigators (2003) E-SIRIUS: 8-month efficacy results. Symposium "Enter the drug-eluting stent revolution II: a clinical appraisal." 03/03 Chicago
59. Serruys PW, Luijten HE, Beatt KJ et al (1988) Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. Circulation 77:361-371
60. Serruys PW, de Jaegere PPT et al for the BENESTENT Study Group (1994) A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331:489-495
61. Serruys PW, van Hout B, Bonnier H et al (1998) Randomized comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II). Lancet 352:673-681
62. Serruys PW (2002) ARTS I-the rapamycin eluting stent; ARTS II-the rosy prophecy. Eur Heart J 23:757-759
63. Sigwart U, Puel J, Mirkovitch V et al (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316:701-706
64. Sousa JE, Costa MA, Abizaid A et al (2001) Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three dimensional intravascular ultrasound study. Circulation 103:192-195
65. Sousa JE, Costa MA, Abizaid A et al (2001) Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one year angiographic and intravascular ultrasound follow-up. Circulation 104:2007-2011
66. Spanos V, Stankovic G, Airoldi F et al (2003) Use of the sirolimus drug-eluting stent for the real world coronary lesions. The Milan experience: results of the first 400 lesions. J Am Coll Cardiol 41:13A
67. Tanabe K, Lemos PA, Lee C et al (2003) The impact of sirolimus-eluting stents on the outcome of patients with bifurcation lesions. J Am Coll Cardiol 41:12A
68. Tanabe K, Serruys PW, Grube E et al (2003) TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107:559-564
69. The BARI Investigators (1997) Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. The bypass angioplasty revascularization investigation (BARI). Circulation 96:1761-1769
70. The writing group for the bypass angioplasty revascularization investigation (BARI) investigators (1997) 5-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. JAMA 277:715-721
71. Teirstein PS, Massullo V, Jani S et al (2000) Three-year clinical and angiographic follow-up after intracoronary radiotherapy. Results of a randomized clinical trial (SCRIPPS). Circulation 101:360-365
72. Topol EJ, Leya F, Pinkerton CA et al for the CAVEAT Study Group (1993) A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med 329:221-227
73. Van Belle E, Périé M, Braune D et al (2002) Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 40:410-417
74. Waksman R, White L, Chan RC et al (200) Intracoronary γ-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis: Washington radiation for in-stent restenosis trial (WRIST). Circulation 101:2165-2171